Last edition
News about "chemotherapy "
Merck Gets Positive EU Opinion for Keytruda-Padcev in MIBC
Merck’s Keytruda plus Padcev receives a positive CHMP opinion for perioperative treatment of adults with resectable muscle-invasive bladder cancer, with the EC set to review the recommendation.
Chemotherapy | 19/09/2026 | By News Bureau
AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC
DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.
Chemotherapy | 16/09/2026 | By News Bureau
AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC
DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.
Chemotherapy | 16/09/2026 | By News Bureau
BeOne Medicines reports positive Phase 3 results showing improved overall survival with Ziihera-based regimens in patients with HER2-positive gastroesophageal adenocarcinoma.
Chemotherapy | 01/09/2026 | By News Bureau
BeOne Medicines reports positive Phase 3 results showing improved overall survival with Ziihera-based regimens in patients with HER2-positive gastroesophageal adenocarcinoma.
Chemotherapy | 01/09/2026 | By News Bureau
GSK's Jemperli Receives FDA Priority Review for dMMR/MSI-H Locally Advanced Rectal Cancer
GSK’s Jemperli has received FDA priority review for previously untreated dMMR/MSI-H locally advanced rectal cancer, following positive phase 2 AZUR-1 results.
Chemotherapy | 26/08/2026 | By News Bureau | 116
Roche Canada Completes pCPA Negotiations for Perjeta in Early HER2-Positive Breast Cancer
Roche Canada has completed pCPA negotiations for Perjeta in combination with trastuzumab and chemotherapy for eligible patients with HER2-positive early-stage breast cancer, bringing the treatment closer to potential public reimbursement across Canada.
Chemotherapy | 20/08/2026 | By News Bureau
Diakonos Oncology Phase II Glioblastoma Trial Cleared to Continue After DSMB Safety Review
Independent safety review clears Diakonos Oncology’s Phase II DOC1021 glioblastoma trial to proceed, with no safety concerns identified to date.
Chemotherapy | 18/02/2026 | By News Bureau | 232
First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC
The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.
Chemotherapy | 14/01/2026 | By News Bureau | 338
Phanes Therapeutics Presents First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer
Early data from the Twinpeak study presented at ASCO GI 2026 show encouraging safety and efficacy of spevatamig combined with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma.
Chemotherapy | 12/01/2026 | By News Bureau | 382
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy